- Home
- DVAX vs IGIC Comparison
DVAX vs IGIC Comparison
Compare DVAX & IGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- IGIC
- Stock Information
- Founded
- DVAX 1996
- IGIC 2001
- Country
- DVAX United States
- IGIC Jordan
- Employees
- DVAX N/A
- IGIC N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- IGIC Property-Casualty Insurers
- Sector
- DVAX Health Care
- IGIC Finance
- Exchange
- DVAX Nasdaq
- IGIC Nasdaq
- Market Cap
- DVAX 1.2B
- IGIC 1.0B
- IPO Year
- DVAX 2004
- IGIC N/A
- Fundamental
- Price
- DVAX $11.21
- IGIC $23.72
- Analyst Decision
- DVAX Buy
- IGIC Buy
- Analyst Count
- DVAX 4
- IGIC 2
- Target Price
- DVAX $26.50
- IGIC $31.50
- AVG Volume (30 Days)
- DVAX 1.7M
- IGIC 100.5K
- Earning Date
- DVAX 11-05-2025
- IGIC 11-04-2025
- Dividend Yield
- DVAX N/A
- IGIC 4.48%
- EPS Growth
- DVAX N/A
- IGIC N/A
- EPS
- DVAX N/A
- IGIC 2.81
- Revenue
- DVAX $330,514,000.00
- IGIC $525,808,999.00
- Revenue This Year
- DVAX $23.23
- IGIC $6.05
- Revenue Next Year
- DVAX $16.57
- IGIC $7.01
- P/E Ratio
- DVAX N/A
- IGIC $8.34
- Revenue Growth
- DVAX 26.73
- IGIC 3.88
- 52 Week Low
- DVAX $9.20
- IGIC $20.82
- 52 Week High
- DVAX $14.63
- IGIC $27.76
- Technical
- Relative Strength Index (RSI)
- DVAX 64.07
- IGIC 62.54
- Support Level
- DVAX $10.97
- IGIC $21.77
- Resistance Level
- DVAX $11.43
- IGIC $23.09
- Average True Range (ATR)
- DVAX 0.36
- IGIC 0.65
- MACD
- DVAX 0.07
- IGIC 0.24
- Stochastic Oscillator
- DVAX 86.42
- IGIC 92.67
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.